Furthermore, immunotherapy efforts are beginning to leverage these vulnerabilities; notably, mesothelin was identified as a surface antigen on human meningiomas, and CAR T cells targeted against mesothelin had robust cytotoxicity and durable regression of tumor in patient-derived organotypic cultures and orthotopic xenografts, providing the first preclinical rationale for CAR T therapy in treatment-refractory meningiomas [25]. The gene discussed is MSLN; the disease is meningioma.